Popular Articles
Revitol Cellulite Cream

DNA Computation Gets Logical At The Weizmann Institute Of Science
Biomolecular computers, made of DNA and other biological molecules, only exist today in a few specialized labs, remote from the regular computer user. Nonetheless, Tom Ran and Shai Kaplan, research students in the lab of Prof. Ehud Shapiro of the Weizmann Institute"s Biological Chemistry, and Computer Science and Applied Mathematics Departments have found a way to make these microscopic computing devices "user friendly," even while performing complex computations and answering complicated queries. Don't forget to buy zoloft online no prescription.

Legislation Needed To Boost HIV/AIDS Efforts In Solomon Islands, Health Official Says
Isaac Muliloa -- national coordinator of the HIV and sexually transmitted infections unit at the Solomon Islands" Ministry of Health -- recently said that a lack of national HIV/AIDS laws is hindering efforts to address the disease, the Solomon Times reports. Recent World Health Organization estimates said that the number of HIV cases in the Solomon Islands could reach 350 by 2010. Muliloa said that legislation is needed to address continued discrimination against HIV-positive employees in the workplace. He added that the HIV/AIDS and STI unit is relatively new in the health ministry, as is the Solomon Islands" National AIDS Council. According to Muliloa, officials are continuing to work toward implementing policies. The Times reports that the Solomon Islands does not have laws in place criminalizing the intentional transmission of HIV (Solomon Times, 5/27).

generic viagra online


News of the day
Novel Mechanism Controlling Tumor Growth In The Brain Revealed By Scripps Research Scientists
As survival rates among some patients with cancer continue to rise, so does the spread of these cancers to the brain - as much as 40 percent of all diagnosed brain cancers are considered metastatic, having spread from a primary cancer elsewhere in the body.
Health Insurance

Spectrum Pharmaceuticals Receives Complete Response Letter From FDA For Zevalin

Spectrum Pharmaceuticals (NasdaqGM:SPPI), a commercial-stage biotechnology company with a focus in oncology, announced that it has received a Complete Response letter from the U.S. Food and Drug Administration (FDA) regarding its supplemental Biologics License Application (sBLA) for ZEVALIN® (ibritumomab tiuxetan) in the first-line consolidation setting for non-Hodgkin"s Lymphoma (NHL) patients. The Prescription Drug User Fee Act (PDUFA) Action Date for the ZEVALIN sBLA in the first-line consolidation setting was July 2, 2009. ZEVALIN is currently FDA approved and marketed by Spectrum for the treatment of patients with relapsed or refractory, low-grade or follicular B-cell NHL, including patients who have rituximab-refractory follicular NHL. The FDA requested the Company to submit data files from the FIT study to support and verify a subset of the data that are currently under review to support the proposed labeling. Importantly: 1) No additional clinical studies have been requested; 2) The additional data requested do not involve new data analyses; 3) The Company plans to formally respond to the FDA"s requests by this Wednesday, July 8, 2009. Spectrum is confident that the data it will submit will satisfy the requirements of the Complete Response letter, and, at this time, continues to expect a favorable regulatory decision. Spectrum Pharmaceuticals


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):